PBM
NASDAQ HealthcarePsyence Biomedical Ltd. - Ordinary Shares
Biotechnology
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
๐ Market Data
| Price | $6.25 |
|---|---|
| Volume | 1,062,081 |
| Market Cap | 14.33M |
| Beta | 0.310 |
| RSI (14-Day) | 60.3 |
| 200-Day MA | $76.52 |
| 50-Day MA | $3.75 |
| 52-Week High | $468.36 |
| 52-Week Low | $1.92 |
| Price / Book | 0.16 |
๐ฏ Investment Strategy Scores
PBM scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (99/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Moon Shot (17/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find PBM in your text
Paste any article, transcript, or post โ the tool will extract PBM and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.